Fibrosis in chronic and delayed myocardial injury
Research type
Research Study
Full title
Fibrosis in chronic and delayed myocardial injury
IRAS ID
300754
Contact name
Marc Dweck
Contact email
Sponsor organisation
The Queen's Medical Research Institute
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
We aim to examine the role that scarring plays in heart conditions such as aortic stenosis (narrowing of the aortic valve), heart injury due to chemotherapy and carcinoid syndrome (a rare cancer that causes secretion of hormones into the bloodstream). Scarring, also known as fibrosis, is a common final result following any injury to the heart muscle and we here, aim to identify this process early and in its active state. This will be examined by using a radioactive dye (radiotracer), specifically 68Ga-FAPI or 18F-AlF-FAPI, and performing a specialised MRI and CT scans called, PET-MR, or PET-CT of the heart.
These tracers have been safely used in humans so far, demonstrate acceptable radiation doses and have given very good results in demonstrating active scarring in the body. They have been extensively used in cancer patients but we will be specifically looking at the heart.
In this study we will explore whether the active scarring is increased in patients with narrowing of the aortic valve (aortic stenosis), heart injury due to previous chemotherapy (chemotherapy-induced cardiotoxicity) and hormone-secreting tumours (carcinoid syndrome) is increased compared to healthy volunteers with normal hearts.
REC name
South East Scotland REC 01
REC reference
22/SS/0003
Date of REC Opinion
14 Feb 2022
REC opinion
Further Information Favourable Opinion